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Abstract Mutational analysis based on pharmacological differ- 
ences between mammalian and amphibian angiotensin II 
receptors (AT receptors) previously led to construction of a 
mutant receptor that gained > 25000-fold affinity for the 
biphenylimidazole, Losartan. This variant frog receptor also 
bound with high affinity other nonpeptides in the biphenylimida- 
zole chemical class according to the following rank order of 
potency (expressed in Fmu t values= mutant ICsolrAT1b IC50): 
Losartan, 0.91 ; L-162,389, 1.0; L-163,491, 1.9; L-158,809, 3.5; 
L-163,017, 3.9; SC-51,316, 3.9. In contrast, the imidazoleacrylic 
acids, SKF-I08,566 (Fmut= 160) and SB-203,220 (Fm,t = 170), 
bound with markedly less affinity. Thus, nonconserved residues 
determining the molecular requirements for biphenylimidazole 
recognition are conserved in general, but are not identical to 
nonconserved residues necessary for high affinity binding of 
imidazoleacrylic acids, 
Key words: Angiotensin AT1 receptor; Nonpeptide 
antagonist; Biphenylimidazole; Imidazoleacrylic a id; Site- 
directed mutagenesis 
I. Introduction 
The fact that the renin-angiotensin ystem (RAS) plays a 
critical role in the control of blood pressure and water and 
electrolyte homeostasis [1] has led to pharmaceutical interven- 
tion in the RAS as an effective treatment of hypertension and 
congestive heart failure [2]. The effector hormone in the RAS 
is the octapeptide angiotensin II (Ang II), which exerts its 
effects through type-1 (AT1) and type-2 (AT2) receptors lo- 
cated in the plasma membrane. These cloned peptide hormone 
receptors belong to the seven transmembrane (TM) domain 
superfamily of G-protein coupled receptors [3]. The AT~ re- 
ceptor mediates all of the classic effects of Ang II on cardio- 
vascular and renal function whereas the function of the AT~ 
receptor is not as yet well understood [2,4]. 
Discovery of the prototype CV-2947 compound, which is a 
specific nonpeptide antagonist of the AT1 receptor and orally 
active [5], has led to the development of two series of nonpep- 
tide receptor antagonists. The majority of these compounds 
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are biphenylimidazole d rivatives while a second series is de- 
rived from imidazoleacrylic a ids (Fig. 1). Although different 
strategies were employed in the development of these com- 
pounds, both approaches were based on molecular modeling 
of Ang II. The biphenylimidazoles were developed from align- 
ing the imidazole of CV-2947 with the imidazole of His 6 in 
Ang II [6] whereas alignment of the CV-2947 imidazole with 
the aromatic omponent of Pro 7 led to the imidazoleacrylic 
acid nonpeptides [7]. 
Compounds from both classes of nonpeptides are potent 
ligands of the mammalian AT1 receptor but have little affinity 
for amphibian AT receptors [8-12]. We previously employed 
interspecies amino acid exchange to create single point and 
combinatorial mutations of the rat (rATio,) and frog (xATa) 
receptors [9,13]. These studies identified 13 nonconserved ami- 
no acids in TM domains that are crucial to the formation of a 
Losartan (biphenylimidazole) binding site on the rATn, recep- 
tor as evidenced by construction of a combinatorial mphi- 
bian mutant receptor, xCM46, which exhibited an affinity for 
Losartan that was identical to the wild type rATlb receptor 
[13]. In the present study, we examined whether the residues 
identified in the gain-of-fimction xCM46 mutant (Fig. 2), de- 
fined a general nonpeptide binding pocket for biphenylimida- 
zoles and/or imidazoleacrylic a id nonpeptide ligands. 
2. Materials and methods 
2.1. Ligands 
Angiotensin If, [SaP,lleS]angiotensin I1 and [Sarl,AlaS]angiotensin 
II were purchased from Peninsula Laboratories (Belmont, CA). The 
nonpeptide antagonists were kindly provided as follows: SK&F- 
108,566 and SB-203,220 (J. Weinstock, SmithKline Beecham Pharma- 
ceuticals, King of Prussia, PA); L-163,017, L-162,313, L-163,491 and 
L-162,389 (W.J. Greenlee, Merck, Sharp&Dohme, Rahway, NJ), SC- 
51,316 (G.M. Olins, Searle&Co., St. Louis, MO) and Losartan (P.C. 
Wong, DuPont Pharmaceutical Co., Wilmington, DE). 
2.2. Transfections and cell culture [9,13] 
The monkey kidney epithelial COS-7 cell line was cultured in Dul- 
becco's modified Eagle's medium (DMEM) with 4.5 g/l glucose and 
4 mM glutamine supplemented with 10% fetal calf serum, and 1% 
penicillin/streptomycin in a humidified atmosphere of 5% CO2 and 
95% air. Three days after plating in tissue culture flasks (2 × 106 cells/ 
150 cm2), the cells were transfected with 50 p,g of plasmid DNA coding 
for rATlb [14], xAT~ [15], and the combinatorial mutant, xCM46 [13] 
cloned into pCDNAI/AMP using the calcium phosphate method. 
2.3. Membrane preparation [9,13] 
Two days after transfection, the medium was replaced with l0 ml of 
ice-cold Versene. After 10-15 min incubation, the COS-7 cells were 
removed from the flask by trituration, pelleted by centrifugation at
4°C for 10 min at 1000×g, and washed twice in 30 ml of Hanks' 
balanced salt solution. The washed cells were resuspended in 3 ml of 
buffer A (10 mM Tris-HC1, pH 7.4; 5 mM EDTA) and disrupted by 
two cycles of freeze-thawing. The membranes were then washed twice 
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Fig. 1. Structure of angiotensin receptor nonpeptide ligands. 
SB-203,220 
with buffer B (50 mM Tris HC1, pH 7.4; 5 mM MgCI2) by pelleting at 
4°C for 15 min at 10 000 × g, resuspended in buffer B by homogenizing 
with a disposable Pellet Pestle, and analyzed for protein content using 
the Bradford protein reagent (Bio-Rad). The membranes were then 
frozen and stored at -70°C until used for receptor binding assays. 
2.4. Binding assays [9,13] 
Monoiodinated 125I-[Sarl,IleS]Ang II was obtained from Peptide 
Radioiodination Center (Pullman, WA). Cell membrane fractions 
were sonicated for 5 s with a Sonifer Cell Disrupter immediately 
before use in binding assays and incubated (20~,0 gg/tube) for 1-2 
h at room temperature with 100 000 cpm of radioligand and indicated 
concentrations of cold antagonists in 0.3 ml of buffer B containing 
0.1% bovine serum albumin. Binding reactions were terminated by 
rapid filtration and bound radioligand was measured by gamma spec- 
trometry. All determinations were performed in triplicate. Nonspecific 
binding was defined as the binding of radioligand in the presence of 
500 nM cold Saralasin and specific binding was defined as total ra- 
dioligand bound minus nonspecific binding. The IC~0 and Bm~ values 
from the specific binding data were determined by computerized non- 
linear regression analysis using the 'Kaleidagraph' program. 
3. Results and discussion 
The rATlb, xATa and xCM46 receptors expressed in COS-7 
cell membranes exhibited B .... values and affinities towards 
the peptide ligands, Ang II and [Sarl,IleS]Ang ll, which were 
not significantly different between species (Table 1). In con- 
trast, the AT1 nonpeptide ligands had very low affinity for 
xAT~ receptors (ICs0 va lues>50 gM) (Table 1) whereas 
all of the nonpeptide ligands examined had nanomolar  affin- 
ities towards the rATlb receptor with the following rank or- 
der of potency: L-158,809 > SC-51,316 > Losartan > SK&F- 
108,566 > L-163,017 > SB-203,220 > L-163,491 > L-162,389 
(Fig. 3, Table 1). These findings are consistent with previous 
reports demonstrat ing that AT1 nonpeptide ligands are sev- 
eral orders of magnitude less potent at binding amphibian 
xAT compared with mammal ian AT1 receptors [8-12]. 
The pharmacological nd sequence differences in cloned AT 
receptors between species previously facilitated the identifica- 
Table 1 
Binding affinities for AT receptor ligands: wild type and mutant angiotensin II receptors 
Ang II ligands rATlb ICsf~ (nM) xAT~ 
IC~0 (nM) 
xCM46 
F(xATa/rATlb) ICs0(nM) Fnmt 
Peptides 
Angiotensin II 1.0 ± 0.1 1.1 ± 0. I 
[Sarl,IleS]Ang II 2.2 ± 0.1 2.1 ± 0.2 
Biphenylimidazoles 
Losartan 2.2 ± 0.2 > 50 000 
L- 162,389 130 ± 30 > 50 000 
L-163,491 57 ± 30 > 50000 
L-158,809 0.2 ±0.08 > 50000 
L-163,017 13 ± 2 > 50000 
SC-51,316 0.51 ±0.1 > 50000 
Imidazoleacrylic acids 
SK&F-108,566 7.4± 1.6 > 50000 
SB-203,220 32 ± 5 > 50 000 
l 1.4±0.1 1 
1 2.5±0.3 1 
> 25 000 2.0 ± 0.1 0.91 
>380 125 ± 30 1.0 
>880 110 ± 70 1.9 
> 250000 0.7 ± 0.06 3.5 
>3800 51 ± 8 3.9 
> 100000 2 ± 0.3 3.9 
>6800 1200± 200 160 
>1500 5400 ± 700 170 
Data represent the mean of the IC5o values _+ S.E. obtained from three independent experiments each performed in triplicate using 125I[SarX,IleS]Ang 
II as the radioligand. F(xATa/rATlb)=xAT~ ICso/rATlb IC5o; Fmut =xCM46 ICso/rAT~6 ICso. Bm~x values (mean + S.E.M., n = 3-12) in fmol/105 
cells: rATlb, 9.3+ 1.8; xATa, 10± 1.1 ; xCM46, 7.9+ 1.5. 
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Fig. 2. Schematic of the amphibian xATa receptor. Solid circles indicate the residues replaced by mammalian amino acids by site-directed muta- 
genesis to create the combinatorial mutant, xCM46. 
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Fig. 3. Competition binding curves for angiotensin II receptor non- 
peptides. Data are expressed as percent of control (specific bound 
radioligand in the absence of unlabeled ligand). The binding profiles 
of rATlb (B) and the combinatorial xAT~ mutant, xCM46 (rn) for 
nonpeptide antagonists are shown. Representative examples of 3 ~, 
similar experiments (each performed in triplicate) are shown. The 
standard error of each point was less than 10%. ICso values for AT 
receptor ligands are listed in Table 1. 
tion of nonconserved amino acids in the rATlb receptor which 
were critical structural determinants of Losartan binding [9]. 
These studies led to the construction of a combinatorial mu- 
tant of the amphibian AT receptor, xCM46, in which 13 ami- 
no acids in TMII-VII were exchanged for the corresponding 
amino acids in the mammalian rATlb receptor. In contrast to 
the amphibian wild type xAT receptor which did not bind 
Losartan, even at micromolar concentrations, xCM46 exhib- 
ited nanomolar affinity towards Losartan that was indistin- 
guishable from the rATlb wild type receptor [13]. In order 
to determine whether these residues which were influential in 
Losartan binding are of general importance, a series of biphen- 
ylimidazoles were examined for their affinities towards the 
xCM46 mutant (Fig. 3, Table 1). All of the biphenylimidazoles 
examined exhibited affinities towards xCM46 which were 
similar to the rATlb receptor as evidenced by small (1~,) 
Fmut values (= xCM46 ICs0/rATab ICs0). In contrast, the imi- 
dazoleacrylic acid antagonists had large (16~170) Fmut values 
for xCM46 (Fig. 3, Table 1). 
These results uggest that the nonconserved residues which 
determine the molecular equirements for Losartan binding 
are shared within the class of biphenylimidazoles in general 
but are not identical to the nonconserved residues necessary 
for high affinity binding of imidazoleacrylic a ids. Thus, these 
findings are consistent with a previous mutagenesis study of 
the human AT1 receptor in which His 256 in TMVI, highly 
conserved among mammalian and nonmammalian AT recep- 
tors, was shown to interact with imidazoleacrylic a ids but not 
biphenylimidazoles [11]. Although distinct structural determi- 
nants exist, previous reports demonstrate hat there are also 
common points of interaction between these two classes of 
nonpeptides. Interspecies amino acid exchange and alanine 
mutagenesis suggests that Val 1°8 in TMIII [16] and Asn 295 
in TMVII [11] are common structural requirements of biphen- 
ylimidazole and imidazoleacrylic acid binding. Taken to- 
gether, these data indicate that distinct but overlapping mo- 
lecular determinants in the TM region exist for 
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biphenylimidazole and imidazoleacrylic acid recognition on 
the AT1 receptor. 
These findings also support the concept that a common 
binding site for small-molecule ligands is conserved within 
the TM domain of all G-protein coupled receptors regardless 
of the native ligand [17,18]. This is particularly intriguing 
since recent reports suggest that peptide hormone ligands 
such as Ang II are too large too fit within the TM domains 
of their respective receptors and interact with residues in the 
extracellular domains of the receptor [19,20]. Further investi- 
gations into the molecular basis of nonpeptide recognition 
could lead to fundamental insights into the molecular basis 
of ligand recognition for peptide hormone receptors in general 
and provide a rational framework for ligand design for this 
large class of seven TM domain G-protein coupled receptors. 
Acknowledgements: This study was supported by grants from the 
American Heart Association, Nation's Capitol Affiliate and the Na- 
tional Kidney Foundation of the National Capitol Area. 
References 
[1] Raizada, M.K., Phillips, 1.A. and Sumners, C. (1993) Cellular 
and Molecular Biology of the Renin Angiotensin System, CRC 
Press, Boca Raton, FL. 
[2] Timmermans, P.B., Wong, P.C., Chiu, A.T., Herblin, W.F. and 
Smith, R.D. (1993) J. Hum. Hypertens. 7 Suppl. 2, S19 31. 
[3] Sandberg, K. (1994) Trends Endo. Metab. 5, 28-35. 
[4] Timmermans, P.B.M.W.M., Wong, P.C., Chiu, A.T., Herblin, 
W.F., Benfield, P., Carini, D.J., Lee, R.J., Wexler, R.R., Saye, 
J.A.M. and Smith, R.D. (1993) Pharmacol. Rev. 45, 205 251. 
[5] Furukawa, Y., Kishimoto, S. and Nishikawa, K. (1982) United 
States Patent (1982) 4, 340,598. 
V. Nirula et al./FEBS Letters 394 (1996) 361~64 
[6] Smith, R.D., Chiu, A.T., Wong, P.C., Herblin, W.F., and Tim- 
mermans, P.B.M.W.M. (1992) Annu. Rev. Pharmacol. Toxicol. 
32, 135 165. 
[7] Keenan, R.M., Weinstock, J., Finkelstein, J.A., Franz, R.G., 
Gaitanopoulos, D.E., Girard, G.R., Hill, D.T., Morgan, T.M., 
Samanen, J.M., Peishoff, C.E., Tucker, L.M., Aiyar, N., Griffin, 
E., Ohlstein, E.H., Stack, E.J., Weidley, E.F. and Edwards, R.M. 
(1993) J. Med. Chem. 36, 1880-1892. 
[8] Sandberg, K., Ji, H., Millan, M.A. and Catt, K.J. (1991) FEBS 
Lett. 284, 281-284. 
[9] Ji, H., Leung, M., Zhang, Y., Catt, K.J. and Sandberg, K. (1994) 
J. Biol. Chem. 269, 16533-16536. 
[10] Schambye, H., Hjorth, S.A., Bergsma, D.J., Sathe, G. and 
Schwartz, T.W. (1994) Proc. Natl. Acad. Sci. USA 91, 7046 
7050. 
[11] Schambye, H., Hjorth, S.A., Weinstock, J. and Schwartz, T.W. 
(1995) Mol. Pharmacol. 47, 425-431. 
[12] Groblewski, T., Maigret, B., Nonet, S., Larguier, R., Lombard, 
C., Bonnafous, J.C. and Marie, J. (1995) Biochem. Biophys. Res. 
Commun. 209, 153 160. 
[13] Ji, H., Zheng, W., Zhang, Y., Cart, K.J. and Sandberg, K. (1995) 
Proc. Natl. Acad. Sci. USA 92, 9240 9244. 
[14] Sandberg, K., Ji, H., Clark, A.J., Shapira, H. and Catt, K.J. 
(1992) J. Biol. Chem. 267, 9455-9458. 
[15] Ji, H., Sandberg, K., Zhang, Y. and Catt, K.J. (1993) Biochem. 
Biophys. Res. Commun. 194, 756-762. 
[16] Nirula, V., Zheng, W., Sothinathan, R. and Sandberg, K. (1996) 
Br. J. Pharmacol., in press. 
[17] Schwartz, T.W. (1994) Curr. Opin. Biotech. 5, 434444. 
[18] Cascieri, M.A., Gong, T.M. and Strader, C.D. (1995) J. Pharma- 
col. Toxicol. Methods 33, 179-185. 
[19] Hjorth, S.A., Schambye, H.T., Greenlee, W.J. and Schwartz, 
T.W. (1994) J. Biol. Chem. 269, 30953 30959. 
[20] Feng, Y.-H., Noda, K., Saad, Y., Liu, X-p., Husain, A. and 
Karnik, S.S. (1995) J. Biol. Chem. 270, 12846-12850. 
